Literature DB >> 16282732

[A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].

Yoshikazu Fukuda1, Nagahisa Fujio, Toshio Ihara, Hiroshi Takatori, Takashi Tsukazaki, Ikuho Koyama, Yoshito Tsukazaki, Harushi Osugi.   

Abstract

A 50-year-old man was diagnosed with non-resectable scirrhous gastric cancer of antrum accompanied with colon ileus due to direct invasion of the transverse colon. As the ileus improved after cecostomy, chemotherapy with TS-1/cisplatin(CDDP) was performed. Because of no response, 4 cycles of paclitaxel (PTX)/doxifluridine (5'-DFUR) therapy was performed as second-line chemotherapy. Since the stenosis of transverse colon dilated completely and the tumor disappeared, we performed total gastrectomy and right hemicolectomy, and could resect completely. Though 2 cycles of PTX/5'-DFUR therapy was performed postoperatively and the patient's postoperative condition was good, he was suffering from carcinomatous peritonitis complicated by ileus and obstructive jaundice 4 months after operation. He died 1 year after the first medical examination, but his QOL was fairly good for 10 months. PTX/5'-DFUR therapy, which has only slight complications, may be useful for patients with recurrent gastric cancer who had been treated with 5-FU administration as first-line chemotherapy. But the future problem was how to control dissemination after surgery in a resectable case after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282732

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report.

Authors:  Nicola Carlomagno; Fabrizio Schonauer; Vincenzo Tammaro; Annalena Di Martino; Carmen Criscitiello; Michele L Santangelo
Journal:  J Med Case Rep       Date:  2015-01-26

2.  Gastric cancer with large bowel obstruction as the first presentation: A case report.

Authors:  Xiuyan Yu; Junshu Zhang
Journal:  Oncol Lett       Date:  2013-08-22       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.